C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter A—GeneralPart 56—Institutional Review BoardsSubpart C—Irb Functions and Operations

21 C.F.R. § 56.109 (2026)

IRB review of research

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1993–2019 5citing cases
At a glance

Courts have cited this section in 5 opinions since 1993.

(a) An IRB shall review and have authority to approve, require modifications in (to secure approval), or disapprove all research activities covered by these regulations.

(b) An IRB shall require that information given to subjects as part of informed consent is in accordance with § 50.25. The IRB may require that information, in addition to that specifically mentioned in § 50.25, be given to the subjects when in the IRB's judgment the information would meaningfully add to the protection of the rights and welfare of subjects.

(c) An IRB shall require documentation of informed consent in accordance with § 50.27 of this chapter, except as follows:

(1) The IRB may, for some or all subjects, waive the requirement that the subject, or the subject's legally authorized representative, sign a written consent form if it finds that the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside the research context; or

(2) The IRB may, for some or all subjects, find that the requirements in § 50.24 of this chapter for an exception from informed consent for emergency research are met.

(d) In cases where the documentation requirement is waived under paragraph (c)(1) of this section, the IRB may require the investigator to provide subjects with a written statement regarding the research.

(e) An IRB shall notify investigators and the institution in writing of its decision to approve or disapprove the proposed research activity, or of modifications required to secure IRB approval of the research activity. If the IRB decides to disapprove a research activity, it shall include in its written notification a statement of the reasons for its decision and give the investigator an opportunity to respond in person or in writing. For investigations involving an exception to informed consent under § 50.24 of this chapter, an IRB shall promptly notify in writing the investigator and the sponsor of the research when an IRB determines that it cannot approve the research because it does not meet the criteria in the exception provided under § 50.24(a) of this chapter or because of other relevant ethical concerns. The written notification shall include a statement of the reasons for the IRB's determination.

(f) An IRB shall conduct continuing review of research covered by these regulations at intervals appropriate to the degree of risk, but not less than once per year, and shall have authority to observe or have a third party observe the consent process and the research.

(g) An IRB shall provide in writing to the sponsor of research involving an exception to informed consent under § 50.24 of this chapter a copy of information that has been publicly disclosed under § 50.24(a)(7)(ii) and (a)(7)(iii) of this chapter. The IRB shall provide this information to the sponsor promptly so that the sponsor is aware that such disclosure has occurred. Upon receipt, the sponsor shall provide copies of the information disclosed to FDA.

(h) When some or all of the subjects in a study are children, an IRB must determine that the research study is in compliance with part 50, subpart D of this chapter, at the time of its initial review of the research. When some or all of the subjects in a study that was ongoing on April 30, 2001, are children, an IRB must conduct a review of the research to determine compliance with part 50, subpart D of this chapter, either at the time of continuing review or, at the discretion of the IRB, at an earlier date.

[46 FR 8975, Jan. 27, 1981, as amended at 61 FR 51529, Oct. 2, 1996; 66 FR 20599, Apr. 24, 2001; 78 FR 12951, Feb. 26, 2013]
The 5 cases that cite 21 C.F.R. § 56.109 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENObermeier v. Nw. Mem'l Hosp., 2019 IL App (1st) 170553.
cites § 56.109 1×cited by 23 casesunpublished
Where it cites § 56.109
“1-17-0553 process ( 21 C.F.R. § 56.109 (1993)). Thus, Sherman Hospital also had the minimal duty here of checking to ensure that the form its IRB had promulgated was being used.”
Later courts cite it for
“general verdict rendered by the jury creates a presumption that the jury found in favor of a defendant on every defense raised' , as well as a presumption that 'all issues of fact upon which proof was offered were found in favor of the prevailing party' .” · 1 citing court
2
GREENKus v. Sherman Hosp., 644 N.E.2d 1214 (Ill. App. Ct. 2d Dist. 1995).
cites § 56.109 2×cited by 15 cases
Where it cites § 56.109
“( 21 C.F.R. § 56.109 (1993).) In the case at bar, the defense’s expert witness, Earnest Prentice, admitted that, if Sherman Hospital’s IRB had audited any of Dr.”
The case’s holding
A hospital, as well as a physician, may be liable for a patient's defective consent to experimental intraocular lens implantation, and such consent claims are not preempted by federal device law.
Later courts cite it for
“a hospital, as well as a physician, may be held liable for a patient's defective consent in a case involving experimental intraceular lenses.” · 1 citing court
3
GREENPomona Valley Hosp. Med. Ctr. v. Superior Court, 209 Cal. App. 4th 687 (Ct. App. 2012).
cites § 56.109 1×cited by 14 cases
Where it cites § 56.109
“) In addition to approving and monitoring clinical investigations, the IRB’s responsibilities include requiring documentation of informed consent from subjects ( 21 C.F.R. § 56.109 (b), (c) (2012)) and maintaining certain records ( 21 C.”
4
GREENKonrady v. Oesterling, 149 F.R.D. 592 (D. Minn. 1993).
cites § 56.109 2×cited by 4 cases
Where it cites § 56.109
“Included in that responsibility is the *595 duty of an IRB to 1) require that informed consent be obtained from virtually all subjects; 2) require documentation of informed consent ( 21 C.F.R. § 56.109 (b), (c)); and 3) prepare and maintain certain records ( 21 C.”
5
GREENMohr v. Targeted Genetics, Inc., 690 F. Supp. 2d 711 (C.D. Ill. 2010).
cites § 56.109 1×cited by 2 cases
Where it cites § 56.109
“Institutional Review Board ( 21 C.F.R. §§ 56.109 , 312.66; 45 C.F.R. § 46.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320062019

One bar per year. Tallest: 1 case in 1993. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Ill. App. Ct.2Cal. Ct. App.1C.D. Ill.1D. Minn.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com